Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

R&D Systems | Catalog # 4136-KR

R&D Systems
Discontinued Product
4136-KR has been discontinued. View all KIR3DS1/CD158e2 products.

Key Product Details

Source

CHO

Accession Number

Structure / Form

Disulfide-linked homodimer

Applications

Binding Activity
Loading...

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human KIR3DS1/CD158e2 protein
Human KIR3DS1
(His22-His340)
Accession #Q14943
IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

His22

Predicted Molecular Mass

61.9 kDa (monomer)

SDS-PAGE

75-90 kDa, reducing conditions

Activity

Measured by its ability to bind HLA on MDA‑MB‑231 human breast cancer cells.
The ED50 for this effect is 0.03-0.18 μg/mL.

Scientific Data Images for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein Bioactivity

Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein Bioactivity

Recombinant Human KIR3DS1/CD158e2 Fc Chimera (Catalog # 4136-KR) binds to MDA-MB-231 human breast cancer cells. The ED50 for this effect is 0.03-0.18 μg/mL.

Formulation, Preparation, and Storage

4136-KR
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: KIR3DS1/CD158e2

KIR3DS1 (3DS1, CD158e2) is a type I transmembrane protein that belongs to the killer cell Ig-like receptor (KIR) family. KIRs are expressed on CD56dim NK cells and T cell subsets where they differentiate normal from abnormal cells, and regulate effector functions in the innate immune system (1 - 3). KIRs are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails. Like other activating KIRs, KIR3DS1 has a short cytoplasmic tail and a positively charged amino acid (aa) within the transmembrane domain that interacts with the ITAM-bearing signaling adaptor, DAP12 (2, 4). Crosslinking of KIR3DS1 activates cytolysis and induces IFN-gamma production, confirming it to be an activating receptor (4). Approximately 38% of the population expresses KIR3DS1 on the surface of NK cells (1, 4, 5). Variants lacking the N-terminal Ig-like domain and/or with substitutions in the cytoplasmic tail have been described (1, 6). The 50 kDa, 387 aa KIR3DS1 shows 97% aa identity with KIR3DL1 within the ECD, and the two segregate as alleles (3, 7). Some activating KIRs bind weakly to the ligands recognized by their corresponding inhibitory KIR. KIR3DS1 does not bind appreciably to cells transfected with ligands for HLA-Bw4 KIR3DL1 (4, 5). However, HIV-infected people who express the combined phenotype of KIR3DS1 with Bw4 alleles that contain an isoleucine at aa 80, show delayed progression to AIDS and fewer AIDS-related opportunistic infections (7, 8). KIR receptors have no structural orthologs in nonprimates, although mouse Ly-49 proteins perform similar functions (2).

References

  1. Dohring, C. et al. (1996) Immunogenetics 44:227.
  2. Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
  3. Uhrberg, M. et al. (1997) Immunity 7:753.
  4. Carr, W. H. et al. (2007) J. Immunol. 178:647.
  5. O’Connor, G. M. et al. (2007) J. Immunol. 178:235.
  6. Valiante, N. M. et al. (1997) Immunity 7:739.
  7. Martin, M. P. et al. (2002) Nat. Genet. 31:429.
  8. Qi, Y. et al. (2006) PloS Pathog. 2:e79.

Long Name

Killer Cell Immunoglobulin-like Receptor, Three Domains, Long Cytoplasmic Tail, 1

Alternate Names

CD158e2, KIR-G1, nkat10

Entrez Gene IDs

3813 (Human)

Gene Symbol

KIR3DS1

UniProt

Additional KIR3DS1/CD158e2 Products

Product Documents for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

For research use only

Citations for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

Customer Reviews for Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF and earn rewards!

Have you used Recombinant Human KIR3DS1/CD158e2 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes
Loading...